PRTA Prothena Corporation Net Margin

Symbol and logo of brand Prothena Biosciences (PRTA)

High risks of clinical trial failure and regulatory pressure are creating volatility for Prothena Corporation (PRTA). However, the development of protein pathology therapies for the neurodegeneration market expands its potential. Anticipation of Phase 3 data for AL amyloidosis is driving the momentum, where the company's net margin ratio on this GURU.Markets chart demonstrates resilience, and -45.40 reflects the metric's baseline.

Prothena Corporation (PRTA) Net Profit Rate: for the period 07/04/2022 - 11/19/2026

Analytical breakdowns for Prothena Corporation

- share price and expert price forecast:
Summary company analytics:Prothena Corporation - PRTA
Manufactured product of Prothena Corporation PLC

Patent protection for antibodies used in the therapy of neurodegenerative diseases provides Prothena Corporation (PRTA) with an exclusive market advantage under strict FDA oversight. An analysis of financial sales margins allows for an assessment of the net profit share of revenue, revealing the gap between turnover growth and final profitability, which is critical for evaluating the fair value of shares and avoiding the purchase of overvalued assets.

Competitor analysis

BIIB: Net Sales Margin|Net Margin Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Corp) - Net Sales Margin|AXSM: Net Profit Rate|Net Margin acadia-pharm.com (ACAD)|Net Sales Margin Xenon Pharmaceuticals (XENE)|Net Margin Viking Therapeutics VKTX|Net Profit Rate SUPN|CPRX - Net Margin|Net Margin Denali Therapeutics|HRMY: Net Sales Margin|Biohaven - Net Profit Rate|Return on Sales by Net Profit AMLX|Trevi Therapeutics, Inc. (TRVI) - Company Sales Margin|Return on Sales by Net Profit PRAX (Praxis Medicines)|Anavex Corp - Net Return on Sales|Net Margin CeriBell CBLL|alector.com (ALEC) - Net Margin|ANNX: Return on Sales by Net Profit|Net Margin Omeros|NGNE: Net Sales Margin|Return on Sales by Net Profit AC Immune|Return on Sales by Net Profit VYGR|Net Return on Sales NMRA (neumoratx.com)|Return on Sales by Net Profit SCLX (Scilex Holding Company, Inc.)|Net Margin TVGN (Tevogen Bio)|Net Margin Alpha Cognition ACOG|CGTX - Return on Sales by Net Profit|IKT - Net Margin|SAVA: Net Margin|Assertio Therapeutics (ASRT) - Net Margin|Net Margin Coya Therapeutics Inc (COYA)|Net Margin Vistagen|Net Return on Sales OVID (ovidrx.com)|Net Margin Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Net Margin|Alterity Therapeutics Ltd. - Return on Sales by Net Profit|CLNN - Return on Sales by Net Profit|PEPG - Net Margin|Company Sales Margin jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Net Margin|ANVS (Annovis Bio, Inc.) - Net Margin|Net Margin gracetx.com|Net Sales Margin Firefly Neuroscience, Inc.|Net Margin ANEW Medical (KLTO)|NRSN - Net Margin|Net Sales Margin RVPH (Reviva Pharmaceuticals Holdings Inc.)|Company Net Profitability MTVA (metaviatx.com)|NeurAxis Inc. - Net Sales Margin|Company Sales Margin heliusmedical.com HSDT|PASG: Net Sales Margin|Neuphoria - Net Profit Rate|Return on Sales by Net Profit NERV|ATHA: Net Profit Rate|Net Margin Addex Therapeutics Ltd (ADXN)|ALZN (Alzamend Neuro Inc.) - Net Profit Rate|Net Sales Margin CYCN (cyclerion.com)|Net Profitability Margin Protagenic|KTTA: Return on Sales by Net Profit|Net Profit Rate CRGT (cortigent.com)|ATXI: Net Sales Margin|BCLI (BrainStorm Cell Therapeutics) - Net Margin|CARA (Cara Therapeutics Inc.) - Net Sales Margin|Net Margin CHRO|Return on Sales by Net Profit ELYM (Eliem Therapeutics)|Net Margin ITCI (Intra-Cellular Therapies Inc.)|Net Sales Margin LBPH (Longboard Pharma)|Net Sales Margin Marinus Pharmaceuticals Inc MRNS|NKGen Biotech Corp - Net Sales Margin|Net Profit Rate NRBO (NeuroBo Pharma)|SAGE (Sage Therapeutics, Inc) - Return on Sales by Net Profit|Net Return on Sales SNPX|Return on Sales by Net Profit TRVN|Net Margin VIGL|Net Sales Margin WENA|Company Sales Margin Cerevel